BILL ANALYSIS

HR7478

BEARISH

Patient Debt Relief Act

HR7478 (Patient Debt Relief Act) has been assessed with a bearish outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bearish

Market Sentiment

4/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

HR7478 imposes Medicare compliance costs and collection restrictions on hospitals with zero offsetting benefits for for-profits

HCA and UHS have already declined 9.2% and 6% respectively in the trailing 30 days as the market prices this risk

Bill is early-stage (referred to committee) with low near-term passage probability, but regulatory overhang may persist

How HR7478 Affects the Market

The market is correctly discounting HCA and UHS on this regulatory threat. HCA at $429.70 is near its 52-week low of $330; UHS at $168.24 is near $152.33. Both have further downside if the bill gains committee momentum, but also have a potential catalyst for recovery if the bill dies in committee—a likely scenario given the divided Congress. Investors should monitor committee assignments and hearing schedules for Energy & Commerce and Ways & Means.

Bill Details

Metric	Value
Bill Number	HR7478
Market Sentiment	bearish
Event Date	February 10, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

The Patient Debt Relief Act (HR7478) imposes new Medicare compliance costs on hospital operators without providing offsetting reimbursement benefits. For-profit chains HCA and UHS are directly exposed. The bill is early-stage, but both stocks have already declined significantly over the trailing 30 days as the market prices in the regulatory overhang.

Full AI Market Analysis

1) WHAT HAPPENED: HR7478 was introduced February 10, 2026 by Rep. Vasquez (D-NM) with 18 cosponsors, all Democrats. The bill was referred to both the Energy and Commerce Committee and Ways and Means Committee. It has had no subsequent actions—it is early-stage with a long legislative path ahead. 2) MONEY TRAIL: The bill does not authorize or appropriate any new funding. It imposes new regulatory conditions on hospitals that participate in Medicare, with civil monetary penalties up to $1 million per noncompliance instance. The grant program for medical debt relief is authorized but not funded—a separate appropriations bill would be needed. 3) STRUCTURAL WINNERS AND LOSERS: For-profit hospital chains HCA and UHS are the clearest losers. They operate large portfolios of Medicare-dependent hospitals and lack the charitable mission offsets that not-for-profit and public hospitals can claim. Not-for-profit systems like HCA's competitors may face lower net compliance costs due to existing charity care infrastructure. 4) MARKET DATA: Real data confirms the bearish read. HCA fell from $488 on April 17 to $429.70 on April 30—a 9.2% decline. UHS fell from $182.41 to $168.24—a 6% decline. Both are now near their 52-week lows. The selloff accelerated after April 24, suggesting growing market recognition of the bill's potential impact despite its early stage. 5) TIMELINE: The bill faces hearings, markups, floor votes in both chambers, and potential signing. Given unified Democratic sponsorship and a Republican-controlled House, near-term passage is highly unlikely. However, regulatory risk will persist through the 119th Congress, creating continued overhang.